Intracellular signalings underlying bradykinin-induced matrix metalloproteinase-9 expression in rat brain astrocyte-1.
Bradykinin (BK), an inflammatory mediator, has been shown to increase the expression of proteins such as matrix metalloproteinases (MMPs) on brain cells and contributes to the pathophysiology of inflammatory responses. However, the mechanisms regulating MMP-9 expression by BK in rat brain astrocytes-1 (RBA-1) remain unclear. Here we report that the mitogen-activated protein kinase (MAPK) and NF-kappaB pathways participate in the induction of MMP-9 expression induced by BK in RBA cells. Zymographic, Western blotting, and RT-PCR analyses showed that BK increased expression of MMP-9 mRNA and protein in a time- and concentration-dependent manner. BK-induced MMP-9 mRNA and protein expression was inhibited by MEK1/2 inhibitor PD98059, PI3-K inhibitor LY294002, and NF-kappaB inhibitor helenalin. In accordance with these findings, BK-induced phosphorylation of p42/p44 MAPK and Akt and activation of NF-kappaB was attenuated by prior treatment with PD98059, LY294002, and helenalin, respectively. The effects of BK on MMP-9 expression and p42/p44 MAPK and Akt phosphorylation were inhibited by B(2) receptor antagonist Hoe 140, indicating the involvement of B(2) receptors revealed by [(3)H]-BK binding assay. Furthermore, BK-stimulated translocation of NF-kappaB into the nucleus was revealed by Western blotting and immnofluorescence staining and blocked by Hoe140, PD98059, LY294002, and helenalin. Taken together, these results suggest that in RBA cells, activation of p42/p44 MAPK and Akt cascades mediated through NF-kappaB pathway are essential for BK-induced MMP-9 gene expression. This study may provide insights into the regulation of MMP-9 production in CNS, which may occur in vivo in pathological situations such as CNS inflammation and brain astrocytoma.
Hsieh
Hsi-Lung
HL
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC.
Yen
Mao-Hsiung
MH
Jou
Mei-Jie
MJ
Yang
Chuen-Mao
CM
D021581:Active Transport, Cell Nucleus / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002478:Cells, Cultured; D002867:Chromones / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D020935:MAP Kinase Signaling System / Q000502:physiology; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009025:Morpholines / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D012717:Sesquiterpenes / Q000494:pharmacology; D045789:Sesquiterpenes, Guaiane; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D000097782:NF-kappaB-Inducing Kinase
D001920:Bradykinin; D002867:Chromones; D005419:Flavonoids; D020780:Matrix Metalloproteinase 9; D009025:Morpholines; D017346:Protein Serine-Threonine Kinases; D012717:Sesquiterpenes; D045789:Sesquiterpenes, Guaiane; D000097782:NF-kappaB-Inducing Kinase; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C001329:helenalin; C065679:icatibant; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one